News Column

Findings on Influenza A Virus Subtype H1N1 Detailed by Investigators at GlaxoSmithKline [Relative Efficacy of AS03-Adjuvanted Pandemic Influenza...

September 10, 2014



Findings on Influenza A Virus Subtype H1N1 Detailed by Investigators at GlaxoSmithKline [Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial]

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Influenza A Virus Subtype H1N1 are presented in a new report. According to news reporting originating from Rixensart, Belgium, by NewsRx correspondents, research stated, "The vaccine efficacy (VE) of 1 or 2 doses of AS03-adjuvanted influenza A(H1N1) vaccine relative to that of 2 doses of nonadjuvanted influenza A(H1N1) vaccine in children 6 months to California/7/2009(H1N1)-AS03 vaccine at dose 1 and saline placebo at dose 2, 2 doses 21 days apart of A/California/7/2009(H1N1)-AS03 vaccine (the Ad2 group), or 2 doses 21 days apart of nonadjuvanted A/California/7/2009(H1N1) vaccine (the NAd2 group)."

Our news editors obtained a quote from the research from GlaxoSmithKline, "Active surveillance for influenza-like illnesses continued from days 14 to 385. Nose and throat samples obtained during influenza-like illnesses were tested for A/California/7/2009 (H1N1), using reverse-transcriptase polymerase chain reaction. Immunogenicity, reactogenicity, and safety were assessed. There were 23 cases of confirmed 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) infection for the primary relative VE analysis. The VE in the Ad2 group relative to that in the NAd2 group was 76.8% (95% confidence interval, 18.5%-93.4%). The benefit of the AS03 adjuvant was demonstrated in terms of the greater immunogenicity observed in the Ad2 group, compared with the NAd2 group. The 4-8-fold antigen-sparing adjuvanted pandemic influenza vaccine demonstrated superior and clinically important prevention of A(H1N1)pdm09 infection, compared with nonadjuvanted vaccine, with no observed increase in medically attended or serious adverse events."

According to the news editors, the research concluded: "These data support the use of adjuvanted influenza vaccines during influenza pandemics."

For more information on this research see: Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial. Journal of Infectious Diseases, 2014;210(4):545-557. Journal of Infectious Diseases can be contacted at: Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA. (Oxford University Press - www.oup.com/; Journal of Infectious Diseases - jid.oxfordjournals.org)

The news editors report that additional information may be obtained by contacting T. Nolan, GlaxoSmithKline Vaccines, Rixensart, Belgium. Additional authors for this research include S. Roy-Ghanta, M. Montellano, L. Weckx, R. Ulloa-Gutierrez, E. Lazcano-Ponce, A. Kerdpanich, M.A.P. Safadi, A. Cruz-Valdez, S. Litao, F.S. Lim, A.M. de Los Santos, M.A.R. Weber, J.C. Tinoco, M. Hernandez-de Mezerville and Faingezich (see also Influenza A Virus Subtype H1N1).

Keywords for this news article include: Rixensart, Belgium, Europe, Biological Products, Clinical Trials and Studies, Infectious Disease, Influenza A Virus Subtype H1N1, Influenza Vaccines, Orthomyxoviridae, Pediatrics, RNA Viruses, Swine Flu, Swine Influenza, Vertebrate Viruses, Viral Vaccines

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters